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Abstract
Objective
To explore the efficacy of ivermectin in the treatment of serologically diagnosed cases of
Strongyloides stercoralis (S. stercoralis) infection in an Aboriginal community and to
describe factors that may influence the outcome of treatment.
Methods
Longitudinal study of a group of 92 individuals with serologically diagnosed S. stercoralis
treated with ivermectin and followed up over a period of approximately 6 months. Main
outcomes were serological titers pre and post treatment, diabetic status, and duration of
follow up.
Findings
Treatment success was achieved in 62% to 79% of cases dependent on the methods
employed for the diagnosis of infection and assessment of treatment outcome. Type 2 Dia-
betes Mellitus (T2DM) was found to be significantly associated with treatment failure in this
group for two of the three methods employed.
Interpretation
Ivermectin has been confirmed as an effective treatment for S stercoralis infection in this
setting. T2DM appears to be an independent risk factor for treatment failure in this popula-
tion, and plausible mechanisms to explain this observation are presented.
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Author Summary
In this study we examine the treatment of the intestinal worm infection Strongyloides ster-
coralis, a soil transmitted helminth that is common in the developing world and in the
Aboriginal communities of northern Australia. Oral ivermectin is generally accepted as
the treatment of choice for this condition. We screened an Aboriginal community for
Strongyloides infection over the course of 2 years and measured the outcome of treatment
in the 92 cases we found. This study measures the success or otherwise of treatment, and
looks at whether there are any factors that could influence the rate of treatment failure.
The results suggest that ivermectin is an effective treatment for Strongyloides in this set-
ting, and that pre-existing Type 2 Diabetes Mellitus is a risk factor for treatment failure, an
observation of great interest in Aboriginal communities where the prevalence of both con-
ditions is very high. We discuss some possible mechanisms to help explain this previously
unknown relationship.
Introduction
S. stercoralis is a soil transmitted helminth infection and as such is a neglected tropical disease.
It is thought to have a worldwide prevalence of at least 100 million people, and is endemic in
regions where people are in contact with fecal material or contaminated soil. The majority of
infections in the inhabitants of endemic regions are thought to be asymptomatic, but it can
produce a variety of gastrointestinal and skin symptoms. Unusually, S. stercoralis has the
capacity for an auto-infective cycle, and in the presence of host immunosuppression hyper-
infection syndrome may develop, resulting in severe morbidity and even death.[1]
In the past, the absence of a gold standard for the diagnosis of this infection, uncertainty as
to the most effective treatment, and difficulty in establishing whether a cure has been achieved,
has posed problems for research into this condition.[2]
Traditional microbiological methods for detecting strongyloides infection, including con-
centration techniques for fecal examination such as the Baermann and Harada-Mori tech-
niques, and agar plate culture, require the use of repeated, fresh fecal samples, and have been
troubled by low sensitivity. [2] This is particularly so when assessing patients for cure, as larval
output can be low and intermittent leading both to under-estimates of the prevalence of the
infection, and over- estimates of the effectiveness of treatment.[3].
In recent years serological methods for the detection of strongyloides infection have been
developed and advocated as being suitable for both clinical assessment and epidemiological
surveys. Furthermore, there is increasing evidence for the use of serological tests to follow up
treatment and assess cure.[4]
Various medications have been employed for the treatment of strongyloides infection
including albendazole, thiobendazole and ivermectin. It is now generally accepted that iver-
mectin is the most effective treatment and should be the treatment of choice where available,
although questions still remain regarding the best dosing schedule. [3]
Similarly, the best means of follow up after treatment and the appropriate time frame in
which to do this has yet to be established. Follow up of ELISA serology has employed either a
fall from a positive titer to a negative (treatment success), or a proportional fall in titer such
that the ratio of post to pretreatment titers is less than 0.6(treatment effectiveness) [4] The
lengthy time frame required for the follow up of cases has often led to high rates of patients lost
to follow up.[5].
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Strongyloides infection is extremely common in Indigenous communities of the tropical
regions of northern Australia with a prevalence of 41% in some settings.[6,7] Despite increas-
ing access to serological tests and adequate treatment, screening and treatment programs
remain intermittent, and little is known about the efficacy of ivermectin under Australian con-
ditions, with a recent review noting the paucity of adequate follow up studies following treat-
ment. [5]
In this study we report on the treatment and follow up of 92 serologically diagnosed cases of
S. stercoralis infection in a remote Aboriginal community, and the effect of a variety of epide-
miological factors and co-morbidities on the outcome of treatment.
Materials and Methods
Study setting
This study was conducted in three isolated indigenous communities located on the edge of the
Tanami desert in the Kimberley region of Western Australia. The communities are inter-
related and consist of a mobile population of approximately 1200 people. A medical clinic in
each community provides primary care and emergency services, and the nearest hospital and
laboratory services are some 800km away in the town of Broome.
Patients
Prior to this study the approach to testing and treating for helminth infection had been inter-
mittent and largely empirical. Patients suspected of having a worm infection were generally
given a three-day course of albendazole 400mg without any laboratory testing, and very little
ivermectin had been used. In April 2012 it was decided to adopt the best practice guidelines of
the Australian Strongyloides working group [8] and patients attending the clinic were subse-
quently offered testing and treatment on an opportunistic basis for S. stercoralis infection. As
the presumed prevalence of S. stercoralis in the region was about 37% [7], all Indigenous
patients resident in the study communities were considered to be at risk of infection.
Data were extracted including the age, sex, date of testing, S. stercoralis ELISA titer, haemo-
globin, total eosinophil count, percentage eosinophilia, height, weight, calculated BMI, diabetic
status and HbA1C triglyceride level, HDL and total cholesterol. (S1 Dataset)
Eosinophilia was defined as a total eosinophil count of 0.50 x109/L or greater.
T2DM was defined in this group as an HbA1C reading of 6.5% or greater, or a random
blood glucose of more than 11.1 mmol/l, or a fasting blood glucose of more than 7.0 mmol/l,
either at the time of testing, or in the past in patients already receiving treatment for diabetes.
In addition, data were recorded regarding the past treatment, if any, with anthelmintic
drugs. Patients were excluded from the study if they had received past treatment with ivermec-
tin in the absence of serological testing.
The patient group in this study constituted part of that utilized in an earlier published
study. [9]
Serological testing
S. stercoralis ELISA testing was performed by Pathwest Laboratory in Perth Western Australia,
using the commercial Strongyloides IgG ELISA (DRG laboratory). The reference values for this
test were established in a low prevalence (<1/10000) population, with> 0.40 units of absorp-
tion held to be positive,< 0.20 units negative, and values in between considered “equivocal”.
As this study was being conducted in a presumed high prevalence setting, and in the interests
of avoiding false negative results, a modified range was employed. Values greater than or equal
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to 0.30 units were considered positive and treated. All values less than 0.30 units were consid-
ered equivocal and were re-tested after a period of 6 months.
Clinical treatment success was defined as a fall in titer to< 0.30 units. Only patients who
failed to achieve this were, where possible, retreated with ivermectin.
Anthelminthic treatments
Patients identified as positive for S. stercoralis under these criteria were treated with two doses
of ivermectin 0.2 mg/kg given two weeks apart. All patients, whether positive or equivocal,
were recalled for re-testing after a period of 6 months. Although all patients were recalled after
6 months, difficulties in locating subjects for follow up resulted in a wide range (83 to 498 days,
median 214 days) of follow up periods. (S2 Dataset).
Ethics statement
The protocol for this study was approved by the Kimberley Aboriginal Health Planning
Forum. As no tests, treatments or interventions were undertaken apart from those required for
the accepted Australian best practice [8] for the diagnosis and treatment of strongyloides infec-
tion, and all data was de-identified before storage, verbal consent was considered adequate. Lit-
eracy levels in written English are low in the communities studied. All subjects were 21 years of
age or older. Verbal consent was obtained at the time of initial testing and stored electronically.
This approach was endorsed, and subsequent ethical approval for the study was obtained,
through the Western Australian Aboriginal Health Ethics Committee (HREC Reference 515).
Statistical analysis
As the decision to treat at a level of 0.30 units was based only on clinical grounds, and because
the best means for determining treatment failure remains uncertain, the data obtained were
analyzed in three different ways.
The first definition of treatment failure was an initial titer of0.30 units followed by a sub-
sequent post-treatment reading of0.30 units. In a second analysis failure to achieve treatment
“effectiveness”, that is a titer ratio0.60 post-treatment compared to pre-treatment, was the
measure of treatment failure. Lastly, the analysis was repeated using the conventional0.40
units as the cut-off point for positivity, and0.40 units post treatment as the measure of treat-
ment failure.
Descriptive statistics are provided with means, median, percentages and their 95% confi-
dence intervals. Bootstrapping was used to obtain the confidence intervals for medians, whereas
exact binomial confidence intervals are provided for percentages. Comparisons between those
with and without diabetes were tested using independent samples t-tests, Mann-Whitney U-
tests and chi-squared tests for normally distributed continuous variables, skewed continuous
variables and proportions respectively. Log binomial generalized linear models were used to
assess the association between diabetic status and treatment failure after adjusting for age, sex,
initial titer, follow up period and eosinophilia, and HbA1c (%) as a predictor of treatment fail-
ure. All analyses were undertaken using the Stata 13 statistical package.
Results
The characteristics of the 259 patients in this study, and the follow up for the 92 positive cases
are summarized in Tables 1 and 2. Follow up serology was performed in 87 of the 92 patients
treated (94.6%). Of the 5 patients not retested, one was diabetic and 4 were non-diabetic. One
patient had deceased, one was in the prison system and 3 were lost to follow up.
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Treatment failure as defined by a post-treatment titer of0.30 was seen in 38% of patients.
Using the ratio of post-treatment to pre-treatment titer of0.60, 26% of patients had treat-
ment failure. If only those with an initial titer of0.40 and a subsequent reading of0.40 are
defined as a failure, then the treatment failure rate was 21%. The percentage of diabetic and
non-diabetic patients achieving a post treatment titer of< 0.30 is shown graphically. (Fig 1).
T2DM was predictive of treatment failure after adjustment for age, sex, initial titer, follow
up period, treatment interval and eosinophilia, for both cut off points of 0.30 units (p = 0.025)
and 0.40 units (p = 0.006). It was not predictive of failure to achieve treatment “effectiveness”
(post to pretreatment ratio of>0.60) (Table 3).
In addition, follow up of the “equivocal” group (initial titer<0.30, N = 167) over an average
of 220 days revealed only 3 new cases in this period (1.Female age 53, pre titer 0.19 –post 0.30,
2. Female 43, pre 0.15-post 0.43, 3. Female 30, pre 0.18-post 0.30) suggesting that treatment
failures were unlikely to represent incidences of re-infection.
Analysis was performed to determine whether HbA1C, measured as a percentage, was pre-
dictive of treatment failure (defined as post treatment titer 0.30) in the diabetic group and
revealed only a weak positive association (RR 1.085 95% CI 0.963–1.222 p = 0.179).
Discussion
This study confirms the efficacy of ivermectin treatment for strongyloides infection in the set-
ting of an Australian Aboriginal community, although the overall failure rate for treatment is
higher than in some previous studies.[10] The use of serology rather than direct microbiolog-
ical examination for follow up, may in part explain this apparent lower efficacy, as it has been
noted that the low sensitivity of microbiological tests tend to overestimate the efficacy of treat-
ment. [3] [11]
Reliance upon serology alone for diagnosis, rather than traditional microbiological tech-
niques could be perceived as a potential weakness of this study, as it is likely that microscopy
Table 1. Clinical characteristics of the study participants (N = 259).
Variable N Mean, Median or % 95% CI
Age (years) 259 43.4 41.7–45.1
Male 106 40.9% 35.1–47.1
Weight (Kg) 253 81.6 78.9–84.4
BMI (kg/m2) 245 29.7 28.7–30.6
Hb (g/l) 249 133.8 131.7–135.8
HbA1c % 220 6.8a 6.5–7.1
SBP (mmHg) 259 126.8 124.5–129.1
DBP (mmHg) 259 79.7 78.3–81.1
Cholesterol (mmol/l) 228 4.6 4.4–4.7
HDL (mmol/l) 227 0.90 0.87–0.93
Triglycerides (mmol/l) 227 2.1a 1.9–2.3
Diabetes 131 50.6% 44.5–56.7
Eosinophil count 237 0.43a 0.38–0.48
Eosinophil % 236 5.55a 4.71–6.39
E (ELISA) titre 259 0.15a 0.12–0.18
% E-titre  0.3 92 35.5 29.7–41.7
a Median
doi:10.1371/journal.pntd.0003976.t001
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Table 2. Characteristics and outcomes for positive cases by diabetes status with 95% CI.
No diabetes (N = 60) Type 2 Diabetes (N = 32) Sig.a
Age (years) Mean 41.2 (36.9–45.6) 46.8 (42.7–50.9) 0.098
Male (%) 33.3 (22.0–47.0) 50.0 932.0–68.0) 0.119
Weight (Kg) Mean 74.2 (68.6–79.7) 89.4 (68.6–79.7) 0.005
BMI (kg/m2) Mean 27.8 (25.8–29.8) 31.8 (28.3–35.4) 0.031
Hb (g/l) Mean 130.9 (126.1–135.7) 133.4 (126.7–140.1) 0.521
HbA1c % Median 5.9 (5.8–6.0) 8.2 (7.2–9.2) <0.001
SBP (mmHg) Mean 124.0 (119.5–128.6) 134.5 (126.7–142.4) 0.014
DBP (mmHg) Mean 77.3 (74.5–80.0) 83.1 (79.3–86.8) 0.014
Follow up period (Days) Median 215.5 (198.2–232.8) 213.5 (185.4–241.6) 0.921
Initial serology (Titer) Median 0.57 (0.37–0.77) 0.87 (0.68–1.05) 0.244
Days between 1st and 2nd dose 19.5 (15.6–23.4) 16.0 (12.1–19.9) 0.091
ELISA
Post-treatment 0.30 (%) 31.7 (20.3–45.0) 50.0 (31.9–68.1) 0.085
Post-treatment ratio 0.60 25.0 (14.4–38.4) 29.0 (14.2–48.0) 0.683
Pre-treatment >0.40 Post 0.40 16.7 (8.3–28.5) 28.1 (13.7–46.7) 0.196
Eosinophilia (%) 54.5 (40.6–68.0) 71.9 (53.3–86.3) 0.789
aIndependent samples t-tests for continuous variables, Chi-squared tests for categorical variables, Mann-Whitney U-test for skewed continuous variables
doi:10.1371/journal.pntd.0003976.t002
Fig 1. Percentage of diabetic and non-diabetic patients achieving a post-treatment tire of <0.30, with 95% confidence intervals.
doi:10.1371/journal.pntd.0003976.g001
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alone is capable of delivering a specificity of 100%. There is increasing evidence however that
serology is adequate for diagnosis, sero-surveys and follow up of treatment in this condition.
[4], and serology may be superior to microscopy in assessing response to treatment given the
very low sensitivity of microbiological techniques.
The high proportion of patients with T2DM in this study (51%) could also be a contributing
factor, given that T2DM is here demonstrated to be a risk factor for treatment failure. The low
rate of sero-conversion in “equivocal” patients suggests a low incidence of new infections in the
community, and therefore that the apparent treatment failures are unlikely to represent subse-
quent reinfections.
Most notably this study finds that pre-existing T2DM is an independent risk factor for treat-
ment failure when adjusted for age sex, BMI, initial titer, time between treatments, eosinophilia
and duration of follow up.
There are several plausible explanations for the effect of T2DM on treatment outcome.
Firstly, the possibility exists that drug interactions between T2DMmedications and ivermectin,
and the pharmacokinetics of ivermectin, may have some impact on treatment failure rates. The
most commonly used diabetic medications in this study were gliclazide and metformin. There
are no established interactions between gliclazide and ivermectin, and their metabolic path-
ways suggest that an interaction is unlikely. [12, 13]
However, poor absorption is known to be a problem with oral ivermectin. [9] Hyperinsuli-
naemia in itself is known to slow gastric emptying [14] and metformin can produce gastric side
effects including loose bowel actions. It is therefore plausible that impaired absorption of iver-
mectin in diabetic patients taking metformin is a factor in the observed association.
It is also feasible that the altered gut biota known to occur in T2DM patients [15]could
influence the absorption of ivermectin.
The complex nature of the interaction between helminth infections and T2DM could mean
that the nature of the worm infections found in diabetic patients is different. As has been dem-
onstrated elsewhere, helminth infections can in themselves affect glucose metabolism through
a process of immunomodulation [16] and data obtained from this community has confirmed a
strong negative relationship between S. stercoralis infection and T2DM [9]
Consequent to this, it has been suggested that the infections detected in T2DM patients
were more likely to represent relatively recent infections (contracted after the onset of T2DM)
whereas the infections in non-diabetics were more likely to represent chronic, well-adapted
infections with a modified Th2 reaction established in the host. [9] It is known that worm
numbers are likely to be higher in early infections and to fall to lower numbers in chronic infec-
tions. [17] The higher treatment failure rate in patients with T2DM could therefore be due to a
higher average worm burden.
Ivermectin exerts its effect by paralyzing the adult worms, leading to subsequent worm
death, and has little effect on the worm larvae. It may be that relatively early infections in
Table 3. Outcomes for positive cases by diabetes status after adjusting for age, sex, initial titer, follow
up period, days between first and second dose and eosinophilia.
Risk ratio (RR) 95% CI for RR Sig.a
ELISA
Post-treatment 0.30 (%) 1.811 1.076–3.048 0.025
Post-treatment ratio 0.60 1.482 0.698–3.147 0.306
Pre-treatment >0.40 Post 0.40 3.848 1.478–10.019 0.006
aBased on log binomial generalized linear model.
doi:10.1371/journal.pntd.0003976.t003
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patients with T2DM involve higher numbers of auto-infective larvae and that the persistence
of these larvae, with the subsequent re-establishment of a patent infection, is responsible for
the higher treatment failure.
As is well known, T2DM has been implicated in having a negative effect on both the fre-
quency and outcome of various infections in human beings, through a variety of proposed
mechanisms [18,19] and it may be that the observed association simply represents another
example of this process. Though this effect has not to date been described in helminth infec-
tions, case histories have been published describing strongyloides hyper-infection syndrome in
patients where the only known risk factor was T2DM, suggesting that diabetes can play some
role in impairing the immune response to this infection.[20] The fact that treatment failure
was found to be only weakly associated with HbA1C suggests that glycemic control in itself
may not be the main or only factor at play.
Some laboratory evidence exists to suggest that the immune response to helminth infections
in patients with T2DMmay play a role. A recent paper [21] has explored the relationship
between the adipokine resistin, and multiple helminth infections. The authors found that
human resistin was both up-regulated in the period after helminth infection, and that this
increased level of resistin was associated with an enhanced Th1 immune response, increased
worm burden and impaired parasite clearance. They conclude that resistin could have signifi-
cant implications for the outcome of helminth disease in humans and that increased resistin
expression could be predictive of impaired immunity to helminths.
This clearly has implications for individuals with T2DM, as resistin levels have been mea-
sured in relation to obesity, T2DM and the metabolic syndrome, and are known to be variably
increased in these conditions. [22] It may be therefore that the observation that T2DM is a pre-
dictor of treatment failure in S Stercoralis infection reflects once again the presence of a com-
plex and intimate relationship between this helminth infection, the human immune response,
and metabolic illnesses such as T2DM.
Conclusion
This study supports the use of ivermectin for the treatment of strongyloides stercoralis infec-
tion in an Aboriginal community where the disease is endemic. The association of T2DM with
treatment failure in this community suggests that further investigation into the efficacy of iver-
mectin in this group is warranted. A plausible mechanism to explain this observation involving
the adipokine resistin has been described, and further study into the complex relationship
between helminth infection, immunity and metabolic disease would be of value.
Regardless of the mechanism responsible, this study suggests that clinicians should be vigi-
lant when treating T2DM patients for strongyloides infection, ensuring an optimal treatment
regimen and careful follow up for these individuals.
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